Cleary Gottlieb represented GlaxoSmithKline plc and GlaxoSmithKline Capital Inc., a finance subsidiary, in the offering by GlaxoSmithKline Capital Inc. of $2.5 billion of 4.850% Notes due 2013, $2.75 billion of 5.650% Notes due 2018, $2.75 billion of 6.375% Notes due 2038 and $1 billion of Floating Rate Notes due 2010. The notes, issued under a shelf registration statement and wholly and unconditionally guaranteed by GlaxoSmithKline plc, have been listed on the New York Stock Exchange. The offering closed on May 13.
